CEM/C1 (ATCC® CRL-2265)

Organism: Homo sapiens, human  /  Cell Type: T lymphoblast  /  Tissue: peripheral blood  /  Disease: acute lymphoblastic leukemia

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue peripheral blood
Cell Type T lymphoblast
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease acute lymphoblastic leukemia
Age 4 years
Gender Female
Ethnicity Caucasian
Storage Conditions liquid nitrogen vapor phase
Images CRL-2265 Micrograph
Derivation

CEM/C1 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119). The cell line was selected and subcloned in 1991 for resistance to CPT.


Clinical Data
4 years
Caucasian
female
Comments

This cell line exhibits cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT.

CEM/C1 cells are approximately 31 fold less sensitive to CPT than the parental CEM cells.

CEM/C1 cells display atypical multidrug resistance (MDR) and altered topoisomerase I catalytic activity.
Resistance to CPT is stable for up to six months.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing

Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 1- 2 x 105 viable cells/mL. Maintain cultures at cell concentrations between 1 x 105 and 2 x 106 viable cells/mL.


Medium Renewal: 2 to 3 times a week.

Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
Population Doubling Time 26 hrs
Name of Depositor WG Harker
Year of Origin 1991
References

Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731

Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731

Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333